Literature DB >> 32281291

RUNX1 and TGF-β signaling cross talk regulates Ca2+ ion channels expression and activity during megakaryocyte development.

Sanjeev Raghuwanshi1, Swati Dahariya1, Durga Shankar Sharma1, Narasaiah Kovuru1, Itishri Sahu1, Ravi Kumar Gutti1.   

Abstract

Thrombocytopenia is characterized by low platelet count and is typically observed among all preterm and low birthweight neonates admitted to the neonatal intensive care unit. Although the underlying cause for this predisposition is unclear, recent studies have proposed that the intrinsic inability of neonatal hematopoietic stem/progenitor cells to produce mature polyploid megakaryocytes (MKs) may result in delayed platelet engraftment. The developmental and molecular differences between neonatal and adult MKs are not yet fully understood. Previously, we had reported that the key MK transcription factor RUNX1, which is crucial for the regulation of MK specification and maturation, is down-regulated in neonatal MKs when compared with adult MKs. In humans, loss-of-function mutations in RUNX1 cause familial platelet disorder, which is characterized by thrombocytopenia, indicating its crucial role in MK development. However, information about its cross talk with developmentally regulated signaling pathways in MKs is lacking. In this study, we performed a differential gene expression analysis in MKs derived from human cord blood (CB) and adult peripheral blood (PB) CD34+ cells. Further, validation and correlation studies between RUNX1 and transforming growth factor beta (TGF-β) were performed in a differentiating megakaryocytic cell line model. The analysis revealed that TGF-β pathway was the main pathway affected between CB- and PB-MKs. RUNX1 is reported to be a modulator of TGF-β signaling in several studies. The correlation between RUNX1 and TGF-β pathway was analyzed in the PMA-induced megakaryocytic differentiating K562 cells, which exhibit mature megakaryocytic features. The RT2 profiler PCR array analysis revealed that TGF-β pathway components were up-regulated in the PMA-induced megakaryocytic differentiating cells. Furthermore, our study indicated that human TGF-β1 promotes cytosolic calcium (Ca2+ ) activity and MK maturation. We noticed that TGF-β1 increased intracellular free Ca2+ ([Ca2+ ]i) via reactive oxygen species-mediated activation of transient receptor potential (TRP) ion channels. Moreover, we observed that decreased cytosolic Ca2+ activity in the siRUNX1-transfected cells was associated with down-regulation of TRP ion channel expression. Finally, we demonstrated that TGF-β/SMAD signaling augments the development of MKs derived from CB-CD34+ . Present data suggest that RUNX1/TGF-β pathway cross talk is crucial for MK maturation.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  RUNX1; TGF-beta; TRP channel; calcium; megakaryocyte; platelets; thrombocytopenia

Mesh:

Substances:

Year:  2020        PMID: 32281291     DOI: 10.1111/febs.15329

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  3 in total

1.  Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester.

Authors:  Swati Dahariya; Sanjeev Raghuwanshi; Anjali Sangeeth; Mahesh Malleswarapu; Ravinder Kandi; Ravi Kumar Gutti
Journal:  Cancer Immunol Immunother       Date:  2021-04-23       Impact factor: 6.968

2.  Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation.

Authors:  Rujia Zhong; Feng Zhang; Zhen Yang; Yingrui Li; Qiang Xu; Huan Lan; Siegfried Lang; Lukas Cyganek; Elke Burgermeister; Ibrahim El-Battrawy; Xiaobo Zhou; Ibrahim Akin; Martin Borggrefe
Journal:  Front Cardiovasc Med       Date:  2022-02-21

Review 3.  New Insights into TRP Ion Channels in Stem Cells.

Authors:  Jing Guo; Chang Shan; Jiao Xu; Mei Li; Jiayu Zhao; Wei Cheng
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.